Page 2 - Regeneron Eylea News Today

The ranibizumab biosimilar was the first in ophthalmology to the US market in 2022, but its competition has already had a year of interchangeability exclusivity.

BioPharma

Animal studies of a new compound, which can be delivered by eye drop, have found that it can reverse epigenetic changes that lead to wet age-related macular degeneration.

Prestige Biologics, a contract development and manufacturing organization (CDMO), announced it has signed a non-binding MOU with Aurigene…

Read the latest Regeneron headlines - updated 24/7/365. We link to the best sources from around the world. Get the latest on Regeneron...

Friday, the FDA approved Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) approved Eylea HD (aflibercept) Injection 8 mg for wet age-related macular degeneration, diabetic macular edema, 

(For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window) * STOXX 600 up 0.6% * Central banker commentary at Sintra panel in focus ...

(For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window) June 28 (Reuters) - European shares climbed on Wednesday after robust U.S. data soothed concerns about a steep econom...

BioPharma

Industry watchers knew Roche’s Vabysmo would be a threat to Regeneron’s Eylea, but they didn’t foresee just how fast the new dual-action eye drug would grow.…